

Cardiodan®

Pimobendan

Inotropic and vasodilator
for congestive heart failure

**Better
quality
and life
expectancy**



Veterinary Use



petmedica®
Strengthening Bonds

Cardiodan®

Cardiodan® is a medicine based on **pimobendan**, benzimidazolpyridazinone derivative with positive inotropic and vasodilator properties. It is suitable for the treatment of mild, moderate or severe congestive heart failure (CHF).

The use according to medical prescription significantly improves the health, quality and life expectancy of the pet.

Pimobendan is a key component in this treatment. It is beneficial in cases of CHF due to its double action.

1. Positive inotropy to improve contractility without increasing myocardial oxygen demand.
2. Vasodilation to reduce preload and afterload, relieving the workload of the defective heart.




Flavored tablets

CARDIODAN®: YOUR NEW THERAPEUTIC ALLY


Normal anatomy

The normal canine heart has a structure that allows an adequate contractility force for proper ejection and blood flow throughout the body.



Anatomy with DCM

A heart with CHF due to dilated cardiomyopathy (DCM) has enlarged ventricles and ventricular walls are reduced in thickness, which decreases the force of contraction of the heart, decreasing ejection force and blood distribution.



*Some breeds of dogs are more susceptible to CHF caused by dilated cardiomyopathy.

Cardiodan® in action



Dual action: positive inotropic and vasodilator effect.



It acts at the level of the heart muscle and blood vessels.



Different Mechanism from other cardiological drugs.



Improving contractility without increasing oxygen demand.

It can be used alone as monotherapy or along with other therapeutic agents.



More time, better quality of life



Treatment of canine CHF caused by dilated cardiomyopathy or valvular insufficiency.



Treatment in the preclinical stage of DCM, mainly in the Doberman Pinscher breed.



Treatment in the preclinical phase of myxomatous mitral valve disease, delays the onset of clinical signs of heart failure.



In large breed dogs with dilated cardiomyopathy, it delays the onset of CHF or sudden death, prolonging the pet's life.

Dosage and administration

Orally

The dose is 0.25 mg/kg of body weight every twelve hours for a total daily administration of 0.5 mg/kg.

Cardiodan® 1.25 (1.25 mg)

Is used in dogs and cats.



N° of tablets per administration

Morning – Evening



Duration of treatment at the discretion of the veterinarian cardiologist.

BODY WEIGHT KG

	1.25 mg	2.5 mg	5 mg	10 mg
2 - 5	1/2	-	-	-
> 5 - 10	1	-	-	-
> 10 - 20	-	1	1/2	-
> 20 - 40	-	-	1	1/2
> 40 - 60	-	-	2	1
> 60 - 80	-	-	3	1 1/2
> 80	-	-	4	2

Commercial presentation

Cardiodan® is available in 4 presentations depending on the patient's body weight.



Perforated blister

New presentation in Blister Wallet

Allows each tablet to be used without the risk of opening or breaking the adjacent sheets, facilitating administration and daily dosage control.



The slotted tablet can be divided into equal parts which allows the correct adjustment of the dosage.

